We’ve heard what pharmacy organisations have said about the King Review – now we want your opinion
When the interim report of the Review of Pharmacy Remuneration and Regulation was released last week, reactions were mixed.
Some suggestions, such as the removal of medicine price variation and cost-per-unit dispensing remuneration, were criticised by the Guild, while others such as an end to the $1 PBS copayment discount, were welcomed.
Meanwhile, PSA welcomed suggestions such as support for integration of healthcare services, while also expressing concern about the flat dispensing fee.
And wholesalers and Medicines Australia had significant issues with the suggested removal of the CSO.
Readers have weighed in. “There are some positive comments and options for HMRs presented in the King Review,” says contributor Debbie Rigby, while Nick Logan said that, “Taking consumer price negotiations out of dispensing would certainly free up pharmacists for meaningful professional interactions”.
“So far I agree with most of what he has to say except the part about Basing the script fee on an efficient pharmacy model,” said Amandarose. And Philip Smith said that, “the devil is always in the detail”.
We’d like to know what you think about the interim report generally: overall, do you think it has merit? And if so – or not – tell us why in the comments.